These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37745978)

  • 21. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis.
    Cai D; Zhou Z; Wei G; Wu P; Kong G
    Front Genet; 2022; 13():952369. PubMed ID: 36118856
    [No Abstract]   [Full Text] [Related]  

  • 25. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
    Sun S; Wang Y; Wang J; Bi J
    J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological significance of alternative splicing prognostic signatures for bladder cancer.
    Li X; Yang L; Huang W; Jia B; Lai Y
    Heliyon; 2022 Feb; 8(2):e08994. PubMed ID: 35243106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Gao X; Cai J
    Front Genet; 2022; 13():865204. PubMed ID: 35571063
    [No Abstract]   [Full Text] [Related]  

  • 32. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma.
    Mi Y; Wang X
    J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma.
    Wang Y; Zhu H; Wang X
    Front Genet; 2022; 13():965100. PubMed ID: 36186448
    [No Abstract]   [Full Text] [Related]  

  • 35. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
    Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
    Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
    [No Abstract]   [Full Text] [Related]  

  • 36. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
    Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
    Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA).
    Cao R; Yuan L; Ma B; Wang G; Tian Y
    Cancer Cell Int; 2020; 20():276. PubMed ID: 32607061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
    Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
    PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Song J; Zhu M; Zhao S; Ma Y; Yang T
    Front Mol Biosci; 2021; 8():688298. PubMed ID: 34368227
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
    Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
    Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.